VictoryShares US Small Mid Cap Value Momentum ETF (USVM) Quote

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

+170 million
Good luck

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

OMEX: out @ .944 Just have to wait on 07:00 and the other MM's. The gang of 3 won't take my Sell order.
Still watching.

Yep, the global reset one world communist government agenda.

Have not been able to get into any sites of: Rare Element Resources. Is there some problem?

General Mills backs FY25 adjusted EPS view down 1% to up 1%
Backs FY25 organic net sales view flat to up 1%. Backs FY25 adjusted operating profit down 2% to flat. Backs FY25 free cash flow conversion view at least 95%. The company said, "Amid a continued uncertain macroeconomic backdrop for c

Upgrades - Sep 18, 2024

$AMBC: Roth/MKM Upgrades to Buy from Neutral - PT $15 (from $13)
$BAK: UBS Upgrades to Buy from Neutral - PT $10 (from $7.70)
$EXR: Jefferies Upgrades to Buy from Hold - PT $204 (from $162)
$GEHC: BTIG Upgrades to Buy from Neutral - PT $100

Downgrades - Sep 18, 2024

$COR: BofA Downgrades to Neutral from Buy - PT $245 (from $275)
$EW: Jefferies Downgrades to Hold from Buy - PT $70 (from $85)
$INCY: Truist Securities Downgrades to Hold from Buy - PT $74 (from $83)
$POR: Barclays Downgrades to Equalweig

These articles are finally showing up in the MSM now. This isn't Kitco or Zero Hedge talking up gold. A higher gold price over time finally begins to sink in with investors and a bad stock market coupled with geopolitical uncertainty begins to move the Sheeple into safe-haven assets. That's coming.

I agree. Cat man was better by far !!!

Nike price target raised to $84 from $80 at Barclays
Barclays analyst Adrienne Yih raised the firm's price target on Nike to $84 from $80 and keeps an Equal Weight rating on the shares. The firm expects "meaningful pressure" in Nike's fiscal Q1 due to "franchise lifecycle management" and Chin

Please tone it down, we got the point.

How many shares do you count on your post that were at the “Ask”? Read slowly

One cent bid lmao

Not even a fool would be fooled

According to Crunchbase PEC has 101-250 employees

https://www.crunchbase.com/organization/power-engineering-corporation

The way this is going definitely by Friday for sure.

Won't be tradable, too small

mouton29 - Very interesting info. Thank you once again for your exceptional effort and commentary!

So Teoxane most likely cannot just walk with their line but they can't be happy with how Revance stock has performed. If there is trouble with the deal, I'm sure they are right in the

commie party hypocrisy: womens 'choice' vs forced jabs or 'else'

https://media.gab.com/cdn-cgi/image/width=568,quality=100,fit=scale-down/system/media_attachments/files/166/327/463/original/033b7233daab336e.png

So the whale is watching this scam go up and up well now that's a nice way for her to waist her time. Lol

Possible penny break today! $IGPK

Bernstein says iPhone seasonality could be skewed by delayed rollout of AI
Bernstein analyst Toni Sacconaghi notes that reports suggest that the ramp for both iPhone 16 base and Pro models should be relatively normal/strong this year, but iPhone seasonality might be somewhat skewed by the del

Nobody here can hear cause it's typing. All they can do is read.

The Company currently has no plans to appeal the CBOE’s determination and will pursue a listing on the OTCQB, which is more in-line with the Company’s strategic goals. https://www.globenewswire.com/news-release/2024/09/10/2944167/0/en/Vocodia-Receives-Delisting-Notice-from-CBOE-and-Plans-OTCQB-Listi

Broadcom initiated with an Outperform at William Blair
William Blair analyst Sebastien Naji initiated coverage of Broadcom with an Outperform rating. Broadcom is targeting $12B in AI revenue in FY24 and the firm sees room for continued steady growth into FY25 and FY26 driven by increasing cus